Ganetespib and Ziv-Aflibercept in Advanced Cancer

Phase 1, open-label, single-arm trial of ganetespib in gastrointestinal carcinoma, non-small cell lung carcinoma (NSCLC), urothelial carcinoma (UC) and 1 more, sponsored by National Cancer Institute. Primary endpoints: Number of Participants With Serious and Non-serious Adverse Events at 12 months, Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs at 12 months and 1 more. Started Dec 2014; status: terminated.